If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro™ (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How do you treat a tirzepatide overdose?
In the event of an overdosage, contact Poison Control for latest recommendations.
See important safety information, including boxed warning, in the attached prescribing information.
Appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms.1
A period of observation and treatment for these symptoms may be necessary, considering the half-life of tirzepatide is approximately 5 days.1
Enclosed Prescribing Information
1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
Date of Last Review: May 14, 2022